Latest news and press releases about Rocket Pharmaceuticals, Inc. (RCKT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Rocket Pharmaceuticals, Inc., operating alongside its affiliates, is an innovative biotechnology enterprise dedicated to pioneering gene therapies for rare and severely debilitating diseases. The company's active clinical pipeline features multiple promising programs.
Price
| Price | $3.48 |
| Market Cap | $380M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.02 |
| EV / EBITDA | 20.89 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -5.76% |
| Return on Invested Capital | -48.55% |
| Return on Assets | -4.08% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANNX · AURA · AUTL · DBVT · DSGN · GALT · IMAB
Explore sector: Healthcare · Biotechnology
More sections of RCKT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks